LOGIN  |  REGISTER
Assertio
Cue Biopharma

Butterfly Network to Host Investor Day on Monday, March 18, 2024, at the New York Stock Exchange

February 22, 2024 | Last Trade: US$3.12 0.40 -11.36

BURLINGTON, Mass. & NEW YORK / Feb 22, 2024 / Business Wire / Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound, today announced that it will host an Investor Day on Monday March 18, 2024, beginning at 12:00pm ET at the New York Stock Exchange.

During the event, Butterfly’s executive management team will present the Company’s product, software and services portfolio within the point-of-care ultrasound landscape, as well as its strategic initiatives, technology roadmap, and overarching vision. The agenda will include live demonstrations of products, including the newly released, next-generation Butterfly iQ3™.

Speakers will include:

  • President, Chief Executive Officer & Chairman Joseph DeVivo
  • Chief Financial & Operations Officer, Heather Getz
  • Chief Medical Officer, John Martin, MD
  • Chief Technology Officer, Andrei Stoica, PhD
  • Chief Strategy Officer, Darius Shahida
  • Senior Vice President of Home Care, Paula LeClair
  • Senior Director of Global Health, Sachita Shah, MD

Butterfly will also be joined by strategic partners introducing AI tools and novel products that are in co-development.

Attendance at the event will be reserved for analysts and institutional investors. To inquire about attendance at the event, please reach out to This email address is being protected from spambots. You need JavaScript enabled to view it. and This email address is being protected from spambots. You need JavaScript enabled to view it..

A copy of the presentation materials and replay of the event will be available following the event on Butterfly’s Events & Presentations page on the investor relations website.

About Butterfly Network

Founded by Dr. Jonathan Rothberg in 2011, Butterfly Network is a digital health company with a mission is to democratize medical imaging by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly created the world's first handheld single-probe, whole-body ultrasound system using semiconductor technology, Butterfly iQ. The company has continued to innovate, leveraging the benefits of Moore’s Law, to launch its second generation Butterfly iQ+ in 2020, and third generation iQ3 in 2024 – each with increased processing power and performance enhancements. The disruptive technology has been recognized by TIME’s Best Inventions, Fast Company’s World Changing Ideas, CNBC Disruptor 50, and MedTech Breakthrough Awards, among other accolades. With its proprietary Ultrasound-on-Chip™ technology, intelligent software, and educational offerings, Butterfly is paving the way to mass adoption of ultrasound for earlier detection and remote management of health conditions around the world. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: https://www.butterflynetwork.com/choose-your-country.

Viking Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB